{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:41:48Z","timestamp":1788777708297,"version":"build-2803163510"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.1001\/jamaoncol.2022.0039","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T16:37:53Z","timestamp":1647535073000},"page":"717","source":"Crossref","is-referenced-by-count":51,"title":["Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)"],"prefix":"10.1001","volume":"8","author":[{"given":"Kenneth L.","family":"Kehl","sequence":"first","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna L.","family":"Hillman","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina D.","family":"Tan","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Sands","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Oxnard","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Gillaspie","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wigle","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakun","family":"Malik","sequence":"additional","affiliation":[{"name":"National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"The Winship Cancer Institute of Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[{"name":"University of California at Davis Comprehensive Cancer Center, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center and Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra J.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond U.","family":"Osarogiagbon","sequence":"additional","affiliation":[{"name":"Baptist Cancer Center, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Partners CancerCare, Brigham and Women\u2019s Hospital, and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi220002r2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0003-4975(95)00537-U","article-title":"Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer.","volume":"60","author":"Ginsberg","year":"1995","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"coi220002r3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2017.2993","article-title":"Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent.","volume":"4","author":"Smeltzer","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"coi220002r4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jtho.2020.06.009","article-title":"Survival after mediastinal node dissection, systematic sampling, or neither for early stage NSCLC.","volume":"15","author":"Ray","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"21","key":"coi220002r5","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi220002r6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.athoracsur.2016.07.003","article-title":"Quality measures in clinical stage I non-small cell lung cancer: improved performance is associated with improved survival.","volume":"103","author":"Samson","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"coi220002r7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.athoracsur.2008.02.072","article-title":"Underuse of surgical resection for localized, non-small cell lung cancer among Whites and African Americans in South Carolina.","volume":"86","author":"Esnaola","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"coi220002r8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jtcvs.2019.04.068","article-title":"Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort.","volume":"158","author":"Osarogiagbon","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"coi220002r9","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1097\/JTO.0b013e318189f562","article-title":"Adjuvant chemotherapy uptake in non-small cell lung cancer.","volume":"3","author":"Younis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"coi220002r10","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1200\/JCO.2019.37.15_suppl.6581","article-title":"Low nationwide utilization of adjuvant chemotherapy (AC) in elderly patients with localized non-small cell lung cancer (NSCLC).","volume":"37","author":"Parikh","year":"2019","journal-title":"J Clin Oncol"},{"key":"coi220002r11","author":"Unger","year":"2021","journal-title":"J Clin Oncol"},{"key":"coi220002r12","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"10183","key":"coi220002r13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1\u2013expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"coi220002r14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"coi220002r15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer.","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"coi220002r16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"coi220002r17","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"coi220002r18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi220002r19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study.","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi220002r20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial.","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"coi220002r21","doi-asserted-by":"publisher","journal-title":"J Thorac Oncol","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"issue":"18","key":"coi220002r22","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"coi220002r23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8576","article-title":"A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.","volume":"35","author":"Wakelee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"coi220002r24","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1158\/1078-0432.CCR-15-0354","article-title":"ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer.","volume":"21","author":"Govindan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"coi220002r25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9077","article-title":"ALCHEMIST: adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.","volume":"38","author":"Sands","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9596","key":"coi220002r26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"coi220002r27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cncr.25334","article-title":"Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area.","volume":"117","author":"Allen","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"coi220002r28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.7326\/M13-2946","article-title":"Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study.","volume":"161","author":"Kind","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"coi220002r29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969-1998.","volume":"93","author":"Singh","year":"2003","journal-title":"Am J Public Health"},{"issue":"7","key":"coi220002r30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data.","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"6","key":"coi220002r31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0962280211427759","article-title":"Extension of the modified Poisson regression model to prospective studies with correlated binary data.","volume":"22","author":"Zou","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"404","key":"coi220002r33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1080\/01621459.1988.10478722","article-title":"A test of missing completely at random for multivariate data with missing values.","volume":"83","author":"Little","year":"1988","journal-title":"J Am Stat Assoc"},{"key":"coi220002r34","article-title":"institutional-level differences in quality and outcomes of lung cancer resections in the United States.","author":"Osarogiagbon","year":"2020","journal-title":"Chest"},{"issue":"9","key":"coi220002r35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi220002r36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.lungcan.2004.08.016","article-title":"Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.","volume":"47","author":"Alam","year":"2005","journal-title":"Lung Cancer"},{"key":"coi220002r37","article-title":"Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC.","author":"Wu","journal-title":"J Thorac Oncol"},{"issue":"4","key":"coi220002r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1235","article-title":"Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials.","volume":"1","author":"Unger","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"4","key":"coi220002r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3842","article-title":"Association of patient demographic characteristics and insurance status with survival in cancer randomized clinical trials with positive findings.","volume":"3","author":"Unger","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7511","key":"coi220002r40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma.","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"5","key":"coi220002r41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jtho.2021.01.1618","article-title":"Comparative effectiveness of a lymph node collection kit versus heightened awareness on lung cancer surgery quality and outcomes.","volume":"16","author":"Ray","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"coi220002r42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jtho.2020.12.025","article-title":"Outcomes after use of a lymph node collection kit for lung cancer surgery: a pragmatic, population-based, multi-institutional, staggered implementation study.","volume":"16","author":"Osarogiagbon","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi220002r43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jtcvs.2019.10.102","article-title":"Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery.","volume":"160","author":"Farrow","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"coi220002r32","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical Analysis With Missing Data","author":"Little","year":"2002","edition":"2nd ed"},{"key":"coi220002r1","unstructured":"National Comprehensive Cancer Network. Non-small cell lung cancer, version 4.2021. Accessed March 29, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2790373\/jamaoncology_kehl_2022_oi_220002_1652478708.79534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T15:07:36Z","timestamp":1652972856000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2790373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.0039","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}